Bruker Corporation BRKR is well-poised to grow in the coming quarters due to the solid prospects of the CALID group. Within Bruker Scientific Instruments (“BSI”) Nano, revenue momentum is strong ...

Tempus AI’s TEM reimbursement showed modest sequential improvement in the third quarter of 2025, though average blended reimbursement per test continues to lag peers by a meaningful margin. The ...

The diagnostic armamentarium for solid tumors is evolving rapidly, redefining how we detect, stage, stratify, monitor, and ultimately treat cancer. This ...

The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.

No one's crossed the finishing line yet, but drug developer Nyrada is leading the Great Biotech Regatta of 2025 with close to ...

Edmonton, AB – December 22, 2025 – PRESSADVANTAGE – A first in western Canada, access to TIER-1 ENDOSURE testing for the ...

Approaches incorporating rapid or digital PCR, CRISPR, syndromic testing, and multimodal systems reached new milestones this year.

Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the ...

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...

Bruker faced a tough 2024, with aggressive M&A, $600M preferred issuance, rising debt, and execution issues prompting a ...

According to the USDA, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) ...

EFLM recognizes Babson Diagnostics for innovations in sample collection and preparation ...